title: Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer.
abstract: In ovarian cancer, metastasis is typically confined to the peritoneum. Surgical removal of the primary tumor and macroscopic secondary tumors is a common practice, but more effective strategies are needed to target microscopic spheroids persisting in the peritoneal fluid after debulking surgery. To treat this residual disease, therapeutic agents can be administered by either intravenous or intraperitoneal infusion. Here, we describe the use of a cellular Potts model to compare tumor penetration of two classes of drugs (cisplatin and pertuzumab) when delivered by these two alternative routes. The model considers the primary route when the drug is administered either intravenously or intraperitoneally, as well as the subsequent exchange into the other delivery volume as a secondary route. By accounting for these dynamics, the model revealed that intraperitoneal infusion is the markedly superior route for delivery of both small-molecule and antibody therapies into microscopic, avascular tumors typical of patients with ascites. Small tumors attached to peritoneal organs, with vascularity ranging from 2% to 10%, also show enhanced drug delivery via the intraperitoneal route, even though tumor vessels can act as sinks during the dissemination of small molecules. Furthermore, we assessed the ability of the antibody to enter the tumor by in silico and in vivo methods and suggest that optimization of antibody delivery is an important criterion underlying the efficacy of these and other biologics. The use of both delivery routes may provide the best total coverage of tumors, depending on their size and vascularity.
authors.affiliation: Department of Biology, University of New Mexico, Albuquerque, NM USA.|Department of Computer Science, University of New Mexico, Albuquerque, NM USA.
authors.forename: Kimberly Kanigel
authors.initials: KK
authors.lastname: Winner
authors.affiliation: Department of Pathology, University of New Mexico, Albuquerque, NM USA.|Cancer Center, University of New Mexico, Albuquerque, NM USA.
authors.forename: Mara P
authors.initials: MP
authors.lastname: Steinkamp
authors.affiliation: Cancer Center, University of New Mexico, Albuquerque, NM USA.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Lee
authors.affiliation: Department of Physics and Institute of Biocomplexity, Indiana University, Bloomington, IN USA.
authors.forename: Maciej
authors.initials: M
authors.lastname: Swat
authors.affiliation: Department of OB/GYN, University of New Mexico, Albuquerque, NM USA.|Cancer Center, University of New Mexico, Albuquerque, NM USA.
authors.forename: Carolyn Y
authors.initials: CY
authors.lastname: Muller
authors.affiliation: Department of Biology, University of New Mexico, Albuquerque, NM USA.|Department of Computer Science, University of New Mexico, Albuquerque, NM USA.
authors.forename: Melanie E
authors.initials: ME
authors.lastname: Moses
authors.affiliation: Department of Mathematics and Statistics, Georgia State University, Atlanta GA USA.
authors.forename: Yi
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Pathology, University of New Mexico, Albuquerque, NM USA.|Cancer Center, University of New Mexico, Albuquerque, NM USA.
authors.forename: Bridget S
authors.initials: BS
authors.lastname: Wilson
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008962:Models, Theoretical; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D054852:Small Molecule Libraries / Q000494:pharmacology
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D054852:Small Molecule Libraries